Market Research Reports, Inc.

Bacterial Vaginosis - Pipeline Review, H2 2014, New Report Launched

LogoBacterial Vaginosis - Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Bacterial Vaginosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects.

Hidradenitis Suppurativa - Pipeline Review, H2 2014, New Report Launched

LogoHidradenitis Suppurativa - Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Hidradenitis Suppurativa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hidradenitis Suppurativa and special features on late-stage and discontinued projects.

Retinopathy - Pipeline Review, H2 2014, New Report Launched

LogoRetinopathy - Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy and special features on late-stage and discontinued projects.

Rubella - Pipeline Review, H2 2014, New Report Launched

LogoPipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Rubella, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rubella and special features on late-stage and discontinued projects.

Yemen Military Expenditure Is Expected to Increase to US$3.08 Billion by 2019; Finds New Report

LogoThe Future of the Yemeni Defense Industry - Market Attractiveness, Competitive Landscape and Forecasts to 2019 report provides readers with detailed analysis of both historic and forecast defense industry values, factors influencing demand, the challenges faced by industry participants, analysis of industry leading companies, and key news.

Ophthalmics Partnering Terms and Agreements, New Report Launched

LogoProvides comprehensive understanding and unprecedented access t- the ophthalmics partnering deals and agreements entered int- by the worlds leading healthcare companies.

Oncology Partnering Terms and Agreements, New Report Launched

LogoThe Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies

Infectious Vaccines Partnering Terms and Agreements, New Report Launched

LogoThe Infectious Vaccines Partnering Terms and Agreements provides comprehensive understanding and unprecedented access to the infectious vaccines partnering deals and agreements entered into by the worlds leading healthcare companies.

Dermatology Partnering Terms and Agreements, New Report Launched

LogoThe Dermatology Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter dermatology partnering deals.

Antibody Partnering Terms and Agreements, New Report Launched

LogoThe Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.